Radiation-induced Salivary Gland Vascular Injury: Mechanisms and Interventions

辐射引起的唾液腺血管损伤:机制和干预措施

基本信息

  • 批准号:
    10701306
  • 负责人:
  • 金额:
    $ 47.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-22 至 2024-09-21
  • 项目状态:
    已结题

项目摘要

Project Summary Radiation-induced xerostomia (RIX) is the most frequent and permanent late side-effect of RT in head and neck cancer patients that leads to compromised speech, difficulty in eating and swallowing and an overall reduction in quality of life in patients. Sadly, no definitive therapy or effective mitigating strategy is available for routine clinical management of RIX. The development of safe and effective strategies to mitigate RIX has been hindered by limited mechanistic insight and lack of objective methods to characterize the trajectory of normal tissue injury. In this regard, our preclinical studies have revealed that the temporal evolution of radiation- induced vascular injury and DNA damage response is influenced by the host immune status. Our preliminary studies have also revealed that vitamin D (VitD) deficiency exacerbates radiation-induced vascular injury in vivo. Conversely, VitD treatment protects salivary glands from radiation injury in 3D organoids. These observations along with the known anti-inflammatory and antioxidant effects of VitD have led us to hypothesize that correction of VitD deficiency through diet or administration of the active metabolite, calcitriol, can protect salivary glands from radiation damage and alleviate RIX in vivo. To test these hypotheses, we propose to characterize the dynamic changes in vascularity and immune profiles of salivary glands in response to radiotherapy in mice (Aim 1) and evaluate the impact of VitD on preventing/mitigating RIX (Aim 2). A preclinical large animal trial to examine the effects of VitD on response of head and neck tumors and salivary glands to volumetric modulated arc therapy is also proposed (Aim 3). Using novel experimental models and imaging technologies, the application will systematically examine the vascular and immune mechanisms underlying salivary gland radiation injury and define the therapeutic potential of VitD as a radioprotective agent. The proposed studies will enable development of VitD supplementation regimens for prevention of RIX in head and neck cancer patients in the near future.
项目摘要 放射性口腔干燥症(RIX)是头部放疗最常见和最持久的晚期副作用, 颈部癌症患者,导致言语受损,进食和吞咽困难, 降低患者的生活质量。可悲的是,没有明确的治疗或有效的缓解策略, RIX的常规临床管理。制定安全有效的战略来减轻RIX已经成为一项重要的任务。 由于有限的机械洞察力和缺乏客观的方法来描述正常的 组织损伤在这方面,我们的临床前研究表明,辐射的时间演变- 诱导的血管损伤和DNA损伤反应受宿主免疫状态的影响。我们的初步 研究还表明,维生素D(VitD)缺乏会加重辐射诱导的血管损伤, vivo.相反,VitD治疗保护唾液腺免受3D类器官的辐射损伤。这些 观察沿着已知的维生素D的抗炎和抗氧化作用使我们假设 通过饮食或给予活性代谢物骨化三醇纠正VitD缺乏症,可以保护 唾液腺免受辐射损伤并减轻体内RIX。为了验证这些假设,我们建议 描述唾液腺血管分布和免疫谱的动态变化, 在小鼠中进行放射治疗(目的1)并评估VitD对预防/减轻RIX的影响(目的2)。临床前 一项大型动物试验,以检查维生素D对头颈部肿瘤和唾液腺对 还提出了体积调制弧治疗(目标3)。使用新的实验模型和成像 技术,应用程序将系统地检查血管和免疫机制的基础 唾液腺放射损伤和定义的治疗潜力的维生素D作为一种放射防护剂。的 拟议的研究将使维生素D补充方案的发展,以预防RIX在头部和 癌症患者在不久的将来。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mukund Seshadri其他文献

Mukund Seshadri的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mukund Seshadri', 18)}}的其他基金

Acquisition of a 7T MR scanner for Translational Imaging Research at Roswell Park
购买一台 7T MR 扫描仪用于罗斯威尔公园的转化成像研究
  • 批准号:
    10176803
  • 财政年份:
    2021
  • 资助金额:
    $ 47.15万
  • 项目类别:
Radiogenomic Credentialing of Head and Neck Cancer Models
头颈癌模型的放射基因组学认证
  • 批准号:
    10529301
  • 财政年份:
    2020
  • 资助金额:
    $ 47.15万
  • 项目类别:
Radiogenomic Credentialing of Head and Neck Cancer Models
头颈癌模型的放射基因组学认证
  • 批准号:
    10310511
  • 财政年份:
    2020
  • 资助金额:
    $ 47.15万
  • 项目类别:
Non-invasive assessment of salivary gland function: Translational Studies
唾液腺功能的无创评估:转化研究
  • 批准号:
    9082643
  • 财政年份:
    2016
  • 资助金额:
    $ 47.15万
  • 项目类别:
Impact of Vitamin D on the Chemopreventive Efficacy of Erlotinib against Oral Cancer
维生素 D 对厄洛替尼口腔癌化学预防效果的影响
  • 批准号:
    9257368
  • 财政年份:
    2016
  • 资助金额:
    $ 47.15万
  • 项目类别:
Impact of Vitamin D on the Chemopreventive Efficacy of Erlotinib against Oral Cancer
维生素 D 对厄洛替尼口腔癌化学预防效果的影响
  • 批准号:
    10215646
  • 财政年份:
    2016
  • 资助金额:
    $ 47.15万
  • 项目类别:
Photoacoustic Micro-Imaging system for Shared Tumor Imaging Resource at Roswell P
Roswell P 共享肿瘤成像资源的光声微成像系统
  • 批准号:
    8247498
  • 财政年份:
    2012
  • 资助金额:
    $ 47.15万
  • 项目类别:
DEVELOPMENT AND VALIDATION OF AN IMAGING-BASED BIOMARKER OF THERAPEUTIC EFFICACY
基于成像的治疗效果生物标志物的开发和验证
  • 批准号:
    8089501
  • 财政年份:
    2010
  • 资助金额:
    $ 47.15万
  • 项目类别:
DEVELOPMENT AND VALIDATION OF AN IMAGING-BASED BIOMARKER OF THERAPEUTIC EFFICACY
基于成像的治疗效果生物标志物的开发和验证
  • 批准号:
    7990122
  • 财政年份:
    2010
  • 资助金额:
    $ 47.15万
  • 项目类别:
Translational Imaging Shared Resource
转化成像共享资源
  • 批准号:
    10641720
  • 财政年份:
    1997
  • 资助金额:
    $ 47.15万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 47.15万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了